Nonafact

RSS

Withdrawn

This medicine's authorisation has been withdrawn

human coagulation factor IX
MedicineHumanWithdrawn

Lithuanian is available via eTranslation, the European Commission's machine translation service.

Translate to Lithuanian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 13 May 2019, the European Commission withdrew the marketing authorisation for Nonafact (human coagulation factor IX) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanquin Plasma Products B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Nonafact was granted marketing authorisation in the EU on 3 July 2001 for treatment of haemophilia B. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2006. 

The European Public Assessment Report (EPAR) for Nonafact is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (724.48 KB - PDF)

Rodyti

español (ES) (631.1 KB - PDF)

Rodyti

čeština (CS) (1.28 MB - PDF)

Rodyti

dansk (DA) (1.17 MB - PDF)

Rodyti

Deutsch (DE) (1.17 MB - PDF)

Rodyti

eesti (ET) (630.08 KB - PDF)

Rodyti

ελληνικά (EL) (1.32 MB - PDF)

Rodyti

français (FR) (632 KB - PDF)

Rodyti

hrvatski (HR) (651.68 KB - PDF)

Rodyti

italiano (IT) (630.99 KB - PDF)

Rodyti

latviešu (LV) (1.26 MB - PDF)

Rodyti

lietuvių (LT) (654.33 KB - PDF)

Rodyti

magyar (HU) (697.06 KB - PDF)

Rodyti

Malti (MT) (705.64 KB - PDF)

Rodyti

Nederlands (NL) (632.18 KB - PDF)

Rodyti

polski (PL) (677.25 KB - PDF)

Rodyti

português (PT) (630.8 KB - PDF)

Rodyti

română (RO) (652.2 KB - PDF)

Rodyti

slovenčina (SK) (702.68 KB - PDF)

Rodyti

slovenščina (SL) (696.3 KB - PDF)

Rodyti

suomi (FI) (630.29 KB - PDF)

Rodyti

svenska (SV) (631.66 KB - PDF)

Rodyti

Product information

български (BG) (1.46 MB - PDF)

Rodyti

español (ES) (701.19 KB - PDF)

Rodyti

čeština (CS) (2.16 MB - PDF)

Rodyti

dansk (DA) (1.28 MB - PDF)

Rodyti

Deutsch (DE) (1.29 MB - PDF)

Rodyti

eesti (ET) (756.74 KB - PDF)

Rodyti

ελληνικά (EL) (2.52 MB - PDF)

Rodyti

français (FR) (722.23 KB - PDF)

Rodyti

hrvatski (HR) (917.01 KB - PDF)

Rodyti

italiano (IT) (701 KB - PDF)

Rodyti

latviešu (LV) (1.93 MB - PDF)

Rodyti

lietuvių (LT) (881.32 KB - PDF)

Rodyti

magyar (HU) (1.2 MB - PDF)

Rodyti

Malti (MT) (1.22 MB - PDF)

Rodyti

Nederlands (NL) (740.48 KB - PDF)

Rodyti

polski (PL) (1.26 MB - PDF)

Rodyti

português (PT) (723.26 KB - PDF)

Rodyti

română (RO) (883.77 KB - PDF)

Rodyti

slovenčina (SK) (1.23 MB - PDF)

Rodyti

slovenščina (SL) (1.19 MB - PDF)

Rodyti

suomi (FI) (705.99 KB - PDF)

Rodyti

svenska (SV) (718.96 KB - PDF)

Rodyti
Latest procedure affecting product information:IB/0062
24/11/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (678.58 KB - PDF)

Rodyti

español (ES) (658.5 KB - PDF)

Rodyti

čeština (CS) (665.25 KB - PDF)

Rodyti

dansk (DA) (663.15 KB - PDF)

Rodyti

Deutsch (DE) (665.66 KB - PDF)

Rodyti

eesti (ET) (625.82 KB - PDF)

Rodyti

ελληνικά (EL) (692.11 KB - PDF)

Rodyti

français (FR) (657.87 KB - PDF)

Rodyti

italiano (IT) (657.42 KB - PDF)

Rodyti

latviešu (LV) (1.2 MB - PDF)

Rodyti

lietuvių (LT) (644.52 KB - PDF)

Rodyti

magyar (HU) (643.21 KB - PDF)

Rodyti

Malti (MT) (662.72 KB - PDF)

Rodyti

Nederlands (NL) (660.32 KB - PDF)

Rodyti

polski (PL) (665.83 KB - PDF)

Rodyti

português (PT) (658.44 KB - PDF)

Rodyti

română (RO) (647.42 KB - PDF)

Rodyti

slovenčina (SK) (663.13 KB - PDF)

Rodyti

slovenščina (SL) (649.75 KB - PDF)

Rodyti

suomi (FI) (658.13 KB - PDF)

Rodyti

svenska (SV) (661 KB - PDF)

Rodyti

Product details

Name of medicine
Nonafact
Active substance
human coagulation factor IX
International non-proprietary name (INN) or common name
human coagulation factor IX
Therapeutic area (MeSH)
Hemophilia B
Anatomical therapeutic chemical (ATC) code
B02BD04

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Authorisation details

EMA product number
EMEA/H/C/000348
Marketing authorisation holder
Sanquin Plasma Products B.V.

Plesmanlaan 125
NL-1066 CX Amsterdam
The Netherlands

Marketing authorisation issued
03/07/2001
Revision
9

Assessment history

This page was last updated on

Share this page